Sling Therapeutics Patent Portfolio Analysis

A single pulse, dated September 2026

The number is $123M, a Series C announced on 16 September 2026, with TPG, Forbion Capital Partners, The Rise Fund and Sectoral Asset Management named. The company was founded in 2020. Its first patent filing carries a date of 26 June 2023, three years later. So there is a stretch at the beginning with no public paper trail at all, and then a portfolio that starts and grows quickly: one family first filed in 2023, three in 2024, three in 2025.

Set the raise against the last thing the public record shows. The most recent published filing appeared on 17 January 2025. That is twenty months before this pulse. Whatever was filed in between, if anything was, is still inside the eighteen-month publication lag. Investors at this table saw a file. Everyone else is reading a version of it that stops in early 2025.

The money is dated 2026. The readable record stops in January 2025.

Fourteen percent granted, and that matters

Seven families. One granted. Six published and pending. The narrow ribbon is the whole of what is enforceable today; the wide one is the whole of what is still negotiable with an examiner. Fourteen percent is not a failing for a portfolio that began in June 2023. It is what a three-year-old file looks like. Grants on the rest would be expected to land around 2027 on ordinary timelines.

The consequence is that almost all of the value sits in documents whose claims can still shrink. Three of the recent titles run in parallel: use of inhibitors of insulin-like growth factor receptor-1 for fibrotic diseases, for growth hormone IGF-secreting neoplasias, and for ocular-associated disorders. Same mechanism named in the title, three different indications, three separate families. That structure is deliberate. Whether it holds depends on the one granted set of claims and on what the other six survive as.

Eight names, one on more than half

Eight inventors are named across the seven families. Ryan Zeidan appears on four of them. Ronald Dadino appears on two. Gary Douglas Hammer appears on two. Everyone else appears once. That is not a research department. It is a small core with specialists brought in around it, which is the shape you see when a single person is holding the thread and the rest of the file is assembled indication by indication.

It reads as concentration rather than thinness. Four of seven under one name, filed across 2023, 2024 and 2025, means the parallel indication families were not drafted by separate teams working in isolation. They were drafted by people who knew what the others said. For claim scope, that is usually an advantage: the boundaries between the families are more likely to have been drawn on purpose than by accident.

Seven families beside four hundred and sixty

On the same scale, the picture is stark. Over the last five years, University of California filed 460 families in these CPC groups. Novartis filed 446. Inst Nat Sante Rech Med filed 419. Hoffmann La Roche filed 380. Regeneron Pharma filed 351. University of Texas filed 334. Sling Therapeutics has seven. Nothing here says what any of those organisations do; it says only where they file, and they file here in volume.

This is what a crowded classification looks like from the inside. In a space this well worked, count buys nothing. A seventh-of-a-percent share of the filings in a group is not a position, and it was never meant to read as one. What can matter is scope: whether the single granted claim set and the six pending ones stake ground that the 2,400 surrounding filings did not already occupy. That question cannot be settled by size.

In a group this dense, the only thing worth measuring is where the claim boundary falls.

One node pointing back, and it is academic

Exactly one organisation shows up citing these filings: Johns Hopkins University, one citation. For a file whose first document dates from June 2023, that is roughly what you would expect. Citations accumulate slowly, and the six pending families have not been in the public domain long enough to be picked up by examiners or drafters working on later applications elsewhere.

So the single edge is early evidence rather than proof. It tells you the work has been read by somebody outside the company and found close enough to their own to be recorded. It does not yet tell you how the industrial filers in these groups regard it, because none of them have cited it. That signal, if it comes, arrives later, and it arrives in documents nobody can read today.

What the unpublished eighteen months decide

Here is the position plainly. A 2020 company filed its first family in 2023 and reached seven by 2025, with one grant enforceable now and six claim sets still open. The filings name the same receptor mechanism in three different disease titles. All of it is in the US, with PCT. One inventor carries more than half of it. And the raise that validated the whole thing was announced twenty months after the last readable page.

Which means the visible file is not the file. Everything filed since January 2025 is still dark, and the consequential thing about this portfolio is not how many families exist but how wide the claims end up. The parallel indication structure only works if each family holds distinct, defensible ground. In a classification where six organisations filed more than 300 families each, that is the entire question.